Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with surival duration

S. M. Lippman, David S Alberts, D. J. Slymen, S. Weiner, S. A. Aristizabal, A. Luditch, J. R. Davis, E. A. Surwit

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

This article that reports on 70 consecutive patients is one of only a few studies of advanced ovarian cancer that have attempted to define predictive factors associated with survival duration after secondlook laparotomy. As in many other investigations, several factors have been analyzed for predicting second-look outcome. The prognostic variables analyzed in this study included age, stage, histologic grade, residual disease status after initial surgery, and type (cisplatin versus no cisplatin) and number of cycles of chemotherapy. Only stage (P = 0.002) and optimal disease (less than 2 cm residual tumor size) after initial surgery (P < 0.001) were significantly associated with the absence of disease at second-look laparotomy, and both were significant predictors of second-look outcome in a multivariate logistic regression model. Their impact on actuarial survival after second-look laparotomy diminished, however. Actuarial survival after second-look laparotomy was associated with residual tumor size at second-look surgery (P = 0.02). According to second-look findings, the 3-year actuarial survival rates and standard errors were as follows: no pathologic evidence of disease, 80.7% ± 13.4% 3-year survival; microscopic disease plus less than or equal to 2 cm residual disease, 49.1% ± 13.1% survival; and gross residual disease (i.e., greater than 2 cm maximum tumor diameter), 29.5% ± 11.4% survival. We also examined the effect of extensive tumor resection at second-look laparotomy on survival for patients with greater than 2 cm gross residual disease. Optimum resection (less than 2 cm residual tumor mass) resulted in significantly greater survival than suboptimum resection (P < 0.001). This strongly suggests that there is a survial advantage associated with optimum resection at second-look laparotomy.

Original languageEnglish (US)
Pages (from-to)2571-2577
Number of pages7
JournalCancer
Volume61
Issue number12
StatePublished - 1988

Fingerprint

Laparotomy
Carcinoma
Survival
Residual Neoplasm
Cisplatin
Second-Look Surgery
Logistic Models
Ovarian Neoplasms
Neoplasms
Survival Rate
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lippman, S. M., Alberts, D. S., Slymen, D. J., Weiner, S., Aristizabal, S. A., Luditch, A., ... Surwit, E. A. (1988). Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with surival duration. Cancer, 61(12), 2571-2577.

Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with surival duration. / Lippman, S. M.; Alberts, David S; Slymen, D. J.; Weiner, S.; Aristizabal, S. A.; Luditch, A.; Davis, J. R.; Surwit, E. A.

In: Cancer, Vol. 61, No. 12, 1988, p. 2571-2577.

Research output: Contribution to journalArticle

Lippman, SM, Alberts, DS, Slymen, DJ, Weiner, S, Aristizabal, SA, Luditch, A, Davis, JR & Surwit, EA 1988, 'Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with surival duration', Cancer, vol. 61, no. 12, pp. 2571-2577.
Lippman SM, Alberts DS, Slymen DJ, Weiner S, Aristizabal SA, Luditch A et al. Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with surival duration. Cancer. 1988;61(12):2571-2577.
Lippman, S. M. ; Alberts, David S ; Slymen, D. J. ; Weiner, S. ; Aristizabal, S. A. ; Luditch, A. ; Davis, J. R. ; Surwit, E. A. / Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with surival duration. In: Cancer. 1988 ; Vol. 61, No. 12. pp. 2571-2577.
@article{f698aec167304420acfa69bd496e036c,
title = "Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with surival duration",
abstract = "This article that reports on 70 consecutive patients is one of only a few studies of advanced ovarian cancer that have attempted to define predictive factors associated with survival duration after secondlook laparotomy. As in many other investigations, several factors have been analyzed for predicting second-look outcome. The prognostic variables analyzed in this study included age, stage, histologic grade, residual disease status after initial surgery, and type (cisplatin versus no cisplatin) and number of cycles of chemotherapy. Only stage (P = 0.002) and optimal disease (less than 2 cm residual tumor size) after initial surgery (P < 0.001) were significantly associated with the absence of disease at second-look laparotomy, and both were significant predictors of second-look outcome in a multivariate logistic regression model. Their impact on actuarial survival after second-look laparotomy diminished, however. Actuarial survival after second-look laparotomy was associated with residual tumor size at second-look surgery (P = 0.02). According to second-look findings, the 3-year actuarial survival rates and standard errors were as follows: no pathologic evidence of disease, 80.7{\%} ± 13.4{\%} 3-year survival; microscopic disease plus less than or equal to 2 cm residual disease, 49.1{\%} ± 13.1{\%} survival; and gross residual disease (i.e., greater than 2 cm maximum tumor diameter), 29.5{\%} ± 11.4{\%} survival. We also examined the effect of extensive tumor resection at second-look laparotomy on survival for patients with greater than 2 cm gross residual disease. Optimum resection (less than 2 cm residual tumor mass) resulted in significantly greater survival than suboptimum resection (P < 0.001). This strongly suggests that there is a survial advantage associated with optimum resection at second-look laparotomy.",
author = "Lippman, {S. M.} and Alberts, {David S} and Slymen, {D. J.} and S. Weiner and Aristizabal, {S. A.} and A. Luditch and Davis, {J. R.} and Surwit, {E. A.}",
year = "1988",
language = "English (US)",
volume = "61",
pages = "2571--2577",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with surival duration

AU - Lippman, S. M.

AU - Alberts, David S

AU - Slymen, D. J.

AU - Weiner, S.

AU - Aristizabal, S. A.

AU - Luditch, A.

AU - Davis, J. R.

AU - Surwit, E. A.

PY - 1988

Y1 - 1988

N2 - This article that reports on 70 consecutive patients is one of only a few studies of advanced ovarian cancer that have attempted to define predictive factors associated with survival duration after secondlook laparotomy. As in many other investigations, several factors have been analyzed for predicting second-look outcome. The prognostic variables analyzed in this study included age, stage, histologic grade, residual disease status after initial surgery, and type (cisplatin versus no cisplatin) and number of cycles of chemotherapy. Only stage (P = 0.002) and optimal disease (less than 2 cm residual tumor size) after initial surgery (P < 0.001) were significantly associated with the absence of disease at second-look laparotomy, and both were significant predictors of second-look outcome in a multivariate logistic regression model. Their impact on actuarial survival after second-look laparotomy diminished, however. Actuarial survival after second-look laparotomy was associated with residual tumor size at second-look surgery (P = 0.02). According to second-look findings, the 3-year actuarial survival rates and standard errors were as follows: no pathologic evidence of disease, 80.7% ± 13.4% 3-year survival; microscopic disease plus less than or equal to 2 cm residual disease, 49.1% ± 13.1% survival; and gross residual disease (i.e., greater than 2 cm maximum tumor diameter), 29.5% ± 11.4% survival. We also examined the effect of extensive tumor resection at second-look laparotomy on survival for patients with greater than 2 cm gross residual disease. Optimum resection (less than 2 cm residual tumor mass) resulted in significantly greater survival than suboptimum resection (P < 0.001). This strongly suggests that there is a survial advantage associated with optimum resection at second-look laparotomy.

AB - This article that reports on 70 consecutive patients is one of only a few studies of advanced ovarian cancer that have attempted to define predictive factors associated with survival duration after secondlook laparotomy. As in many other investigations, several factors have been analyzed for predicting second-look outcome. The prognostic variables analyzed in this study included age, stage, histologic grade, residual disease status after initial surgery, and type (cisplatin versus no cisplatin) and number of cycles of chemotherapy. Only stage (P = 0.002) and optimal disease (less than 2 cm residual tumor size) after initial surgery (P < 0.001) were significantly associated with the absence of disease at second-look laparotomy, and both were significant predictors of second-look outcome in a multivariate logistic regression model. Their impact on actuarial survival after second-look laparotomy diminished, however. Actuarial survival after second-look laparotomy was associated with residual tumor size at second-look surgery (P = 0.02). According to second-look findings, the 3-year actuarial survival rates and standard errors were as follows: no pathologic evidence of disease, 80.7% ± 13.4% 3-year survival; microscopic disease plus less than or equal to 2 cm residual disease, 49.1% ± 13.1% survival; and gross residual disease (i.e., greater than 2 cm maximum tumor diameter), 29.5% ± 11.4% survival. We also examined the effect of extensive tumor resection at second-look laparotomy on survival for patients with greater than 2 cm gross residual disease. Optimum resection (less than 2 cm residual tumor mass) resulted in significantly greater survival than suboptimum resection (P < 0.001). This strongly suggests that there is a survial advantage associated with optimum resection at second-look laparotomy.

UR - http://www.scopus.com/inward/record.url?scp=0023919026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023919026&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 2571

EP - 2577

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -